HD

D01 Two independent validations of a mutant huntingtin protein (MHTT) assay to support the clinical development of mHTT-targeting therapies in HD
David Hawellek, Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Lauren Boak, Scott Schobel

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A13; DOI: 10.1136/jnnp-2021-EHDN.32
F14 Collaborating with the community to conduct clinical trials in huntington’s disease: lessons from the tominersen phase iii generation HD1 study
Victoria Liddy, David West, Mai-lise Nguyen, Lauren Boak, Scott Schobel, Nolwen Olivier, Keir Hodge, HD-COPE, Jenny Townhill

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A24-A25; DOI: 10.1136/jnnp-2021-EHDN.57
G01 Molecular testing for huntington disease and the risk of disclosure of unsolicited pre-symptomatic status: a recurring theme
Elaine Cristina Miglorini, Karina Carvalho Donis, Raphael Castilhos, Maria Luiza Saraiva-Pereira, Laura Bannach Jardim

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A41; DOI: 10.1136/jnnp-2021-EHDN.98
H01 Disease burden in patients with huntington’s disease from a nationwide swedish registry compared with the general population (2002–2019)
Hannah Furby, Suzanne Moore, Anna-Lena Nordstroem, Richard Houghton, Sophie Graham, Dimitra Lambrelli, Per Svenningsson, Åsa Petersén

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A42-A43; DOI: 10.1136/jnnp-2021-EHDN.101
H03 Experiences of outpatients with huntington’s disease with case management; a qualitative study
Cindy Kruijthof, Jonieke Bredewold, Loes van Dusseldorp

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A44; DOI: 10.1136/jnnp-2021-EHDN.103
I15 Inhibition of S1P degradation is beneficial in the transgenic R6/2 mouse model of huntington disease
Alba Di Pardo, Salvatore Castaldo, Enrico Amico, Luca Capocci, Giuseppe Pepe, Vittorio Maglione

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A93-A94; DOI: 10.1136/jnnp-2018-EHDN.251
I17 Curcumin-supplemented diet preserves body weight and ameliorates intestinal functionality in R6/2 mice
Francesca Elifani, Salvatore Castaldo, Luca Capocci, Paolo Rosa, Elena Montano, Antonella Calogero, Stefania Filosa, Stefania Crispi, Vittorio Maglione, Alba Di Pardo

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A94-A95; DOI: 10.1136/jnnp-2018-EHDN.253
I16 Stimulation of SPHK1 with selective activator K6PC-5 is beneficial in the transgenic R6/2 mouse model of huntington disease
Alba Di Pardo, Salvatore Castaldo, Luca Capocci, Alfredo Giovannelli, Enrico Amico, Se Kyoo Jeong, Vittorio Maglione

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A94; DOI: 10.1136/jnnp-2018-EHDN.252
C05 BRCA mutations are associated with higher CAG numbers found in various polyglutamine disorders
Elisabeth Singer, Ilnaz Sepahi, Annika Sachs dos Santos, Cansu-Ebru Oender, André Koch, Andreas Hartkopf, Olaf Riess, Christopher Schroeder, Huu P Nguyen

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A28; DOI: 10.1136/jnnp-2018-EHDN.76
A27 Targeting glutamine dehydrogenase activity to induce autophagy and ameliorate neuronal degeneration; studies using a drosophila model for huntington’ disease
Paola Bellosta, Chiara Paiardi, Maria E Pasini

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A9-A10; DOI: 10.1136/jnnp-2018-EHDN.25

Main menu

HD

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

HD

Pages